KRAS-IN-5 (Compound Ex 6) is an orally active, selective inhibitor that targets KRAS mutants, including KRASG12D, KRASG12V, and KRASWT, with an impressive GNE IC50 value of 1.3 nM for KRASG12D. By inhibiting KRAS-mediated signaling pathways, such as reducing ERK phosphorylation, KRAS-IN-5 effectively prevents tumor cell proliferation. This compound holds potential for research into cancers associated with KRAS mutations, such as pancreatic cancer, colorectal cancer, and lung cancer.